CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • CAR T Cell Immunotherapy Approved for Adult Non-Hodgkin Lymphoma Patients

    FDA approves new immunotherapy–Yescarta (axicabtagene ciloleucel)–for adult patients with relapsed or refractory non-Hodgkin large B cell lymphoma.

    October 18, 2017| Arthur N. Brodsky, PhD
  • FDA Approves First-In-Class CAR T Cell Immunotherapy for Leukemia

    Children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) can now receive the CD19-targeting CAR T…

    August 30, 2017| Arthur N. Brodsky, PhD
  • Recapping Our 5th Annual Cancer Immunotherapy Month

    The 5th Annual Cancer Immunotherapy Month generated more than 6,000,000 impressions and raised over $500,000.

    July 31, 2017| Arthur N. Brodsky, PhD
  • ASCO17 Recap: 7 Takeaways from the World’s Premier Clinical Cancer Conference

    ASCO17’s presentations reveal that the field of immunotherapy is advancing along many fronts

    June 16, 2017| Arthur N. Brodsky, PhD
  • CNN Highlights Cancer Immunotherapy Advances, CRI’s Pioneering Role

    First-line lung cancer immunotherapy approval results from century-long effort to harness the immune system to fight cancer.

    October 28, 2016| Arthur N. Brodsky, PhD
  • Cancer Research Institute Featured in New York Times Cover Story on Cancer Immunotherapy

    The pioneering work of CRI and its funded scientists are profiled in this special feature from the…

    August 1, 2016| Brian Brewer
  • #AACR16 Update: Vice President Biden and the National Cancer Moonshot Initiative

    VP Biden addresses AACR16 seeking suggestions and solutions.

    April 21, 2016| Arthur N. Brodsky, PhD
  • CRI Meets with the Vice President’s Staff on Moonshot

    CRI and Vice President Biden’s Moonshot Initiative collaborate for the advancement of cancer immunotherapy research.

    February 26, 2016| Jill O'Donnell-Tormey, PhD
  • Business Insider Credits CRI with Pioneering Field of Cancer Immunotherapy

    Jimmy Carter’s successful treatment with immunotherapy is thanks to CRI’s pioneering work, says Business Insider.

    January 6, 2016| Brian Brewer
Previous Page
1 2 3
Next Page

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute